Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO.,

(600196)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Shanghai Fosun Pharmaceutical (Group) : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/20/2019 | 09:15am EST

The company will report its earnings for FY 2018 on 03/25/2019. Generally, the company reports earnings worse than estimates. In recent months, the 13 analysts from Thomson Reuters consensus have revised their EPS estimates downward.

Annual earnings per share is expected at 1.13 CNY for 2018 (- 10.8% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million CNY
Released
Forecast
Spread
12 609
12 958
-2,7%
14 506
14 701
-1,3%
18 534
17 556
5,6%

24 035

28 524
Operating income (EBITDA)
Million CNY
Released
Forecast
Spread
3 954
2 183
81%
2 481
2 553
-2,8%
3 108
3 475
-11%

3 822

4 638
Operating profit (EBIT)
Million CNY
Released
Forecast
Spread
3 297
1 929
71%
1 742
2 024
-14%
2 162
2 319
-6,8%

2 347

3 048
Pre-Tax Profit (EBT)
Million CNY
Released
Forecast
Spread
3 372
3 103
8,7%
3 572
3 852
-7,3%
4 062
4 209
-3,5%

3 760

4 589
Net income
Million CNY
Released
Forecast
Spread
2 460
2 487
-1,1%
2 806
2 890
-2,9%
3 124
3 208
-2,6%

2 869

3 485
EPS
 CNY
Released
Forecast
Spread
1,06
1,06
0,24%
1,20
1,22
-1,3%
1,27
1,31
-3,0%

1,13

1,38
Announcement Date03/29/201603/28/201703/26/2018
Stocks mentioned in the article
ChangeLast1st jan.
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD. -3.86% 25.67 End-of-day quote.14.74%
THOMSON REUTERS CORPORATION -0.53% 94.71 Delayed Quote.44.41%
US DOLLAR / CHINESE YUAN RENMINBI (USD/CNY) 0.01% 7.0388 Delayed Quote.2.31%

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHANGHAI FOSUN PHARMACEUTI
11/01SHANGHAI FOSUN PHARMACEUTICAL : Inside information - proposed overseas listing o..
PU
11/01SHANGHAI FOSUN PHARMACEUTICAL : Connected transaction - entering into the capita..
PU
11/01SHANGHAI FOSUN PHARMACEUTICAL : Inside information - proposed overseas listing o..
PU
11/01SHANGHAI FOSUN PHARMACEUTICAL : Connected transaction - entering into the capita..
PU
10/29SHANGHAI FOSUN PHARMACEUTICAL : 2019 third quarterly report(h shareᦀ..
PU
10/21SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
10/15SHANGHAI FOSUN PHARMACEUTICAL : Announcement - on completion of the issuance of ..
PU
10/08SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in ..
PU
08/26SHANGHAI FOSUN PHARMACEUTICAL GROUP : Half-year results
CO
08/02SHANGHAI FOSUN PHARMACEUTICAL GROUP : Ex-dividend day for final dividend
FA
More news
Financials (CNY)
Sales 2019 28 978 M
EBIT 2019 2 664 M
Net income 2019 3 312 M
Debt 2019 16 439 M
Yield 2019 1,56%
P/E ratio 2019 19,6x
P/E ratio 2020 17,5x
EV / Sales2019 2,74x
EV / Sales2020 2,32x
Capitalization 62 918 M
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 31,64  CNY
Last Close Price 25,67  CNY
Spread / Highest target 44,1%
Spread / Average Target 23,3%
Spread / Lowest Target -14,7%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP